The global urology devices market, valued at $39.23 billion in 2025, is projected to grow at a CAGR of 7.35% to reach $80 billion by 2035. Growth is fueled by rising demand for robotic-assisted surgeries, kidney disease management, and minimally invasive treatments, especially among aging populations. North America leads the market, with the U.S. accounting for the majority of revenue, while Asia Pacific is the fastest-growing region due to expanding healthcare infrastructure and chronic kidney disease prevalence. Key segments include instruments, consumables, and applications like kidney diseases and prostate conditions, with hospitals being the primary end-users.
The U.S. Bankruptcy Court for the Central District of California confirmed the Plan of Liquidation for Oceanwide Plaza LLC, enabling the $470 million sale of the stalled Downtown Los Angeles development to KPC Square, a joint venture between KPC Grou...
Axsome Therapeutics received an "Outperform" rating from BMO Capital due to significant progress in its drug pipeline, including FDA acceptance of its NDA for AXS-12, a narcolepsy treatment with a PDUFA date set for May 1, 2027. The company is also a...
Novartis is set to report its Q2 earnings with analysts expecting an EPS of $2.17 and revenue of $14.07 billion, following a tough Q1 affected by major patent expirations. Despite revenue challenges, the company maintained strong cash flow of $3.30 b...
KeyCorp is set to report earnings with analysts forecasting a 20% increase in earnings per share to $0.42 and an 8% rise in total revenue to $1.97 billion. The growth is mainly driven by a 10% increase in net interest income, fueled by strong commerc...
Several biotech and manufacturing companies saw significant stock declines due to key corporate events. Vision Marine Technologies dropped nearly 24% after shifting its focus from boat manufacturing to a mining project, causing investor uncertainty. ...
